Pioneering mRNA technology - Moderna
Learn how we’re changing the world of medicine. Discover career opportunities, our product pipeline, and browse media resources. Meet Moderna.
Our Story - Moderna
We’re making biotech history. Since 2010, we have worked to build the industry's leading mRNA technology platform. Learn more about Moderna’s history.
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine
Sep 11, 2023 · Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.
Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine ...
Sep 6, 2023 · Clinical trial data from research assay confirmed Moderna's updated COVID-19 vaccine showed an 8.7 to 11-fold increase in neutralizing antibodies against circulating variants, including BA.2.86, EG.5, and FL.1.5.1 variants
Moderna R&D Day Highlights Progress and Strategic Priorities
Sep 12, 2024 · Early results suggest potential decreases in annualized rates of MMA-related hospitalizations and MDEs compared to pre-treatment rates. Moderna is working to identify an optimal dose and continues to engage with the U.S. FDA, via the START Program, and other global regulators.
Moderna Achieves Positive Interim Results from Phase 3 Trial of …
Mar 26, 2024 · Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases.
Moderna's mRNA Platform - Moderna
The mRNA DESIGN STUDIO integrates with Moderna’s automation platforms – directing orders through each phase of mRNA synthesis. Once the order is placed, Moderna’s high-throughput …
Celebrating U.S. FDA Approval of Our Updated COVID-19 Vaccine
I am pleased to announce that the U.S. Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 vaccine for this fall for individuals 12 years of age and older. The updated vaccine composition targets the KP.2 variant, based on guidance from the U.S. FDA.
Moderna Advances Multiple Vaccine Programs to Late-Stage …
Mar 27, 2024 · Moderna is advancing five vaccine candidates against viruses that cause latent infections, all of which are in clinical trials. When latent, a virus is present in the body but exists in a resting state, typically without causing any noticeable symptoms.
Our Mission & Values - Moderna
Our Values Moderna people hold a deep sense of responsibility for each other, patients, the environment and our local communities. Our people live our Values every day. Bold …